Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Dermata Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 8 | 11 | +3 |
| Shares | 264.0K | 130.2K | −133.7K (−50.7%) |
| Value | $1.19M | $226.0K | −$960.0K (−80.9%) |
New holders (7)
Institutions that held Dermata Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 39,248 | $68.0K | 0.00% |
| Two Sigma Investments, LP | 18,697 | $33.0K | 0.00% |
| JPMorgan Chase & Co | 12,137 | $21.0K | 0.00% |
| Sage Capital Advisors,llc | 12,000 | $20.0K | 0.01% |
| Tudor Investment Corp Et Al | 10,205 | $18.0K | 0.00% |
| Morgan Stanley | 500 | $1.00K | 0.00% |
| Total Clarity Wealth Management, Inc. | 500 | $1.00K | 0.00% |
Sold out (4)
Institutions that held Dermata Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| AIGH Capital Management LLC | 175,000 | $786.0K |
| Worth Venture Partners, LLC | 40,075 | $180.0K |
| Virtu Financial LLC | 22,496 | $101.0K |
| UBS Group AG | 189 | $1.00K |